Statements about H.R.2853: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021
One member of Congress have made one statement about this bill.
Date | Member | Party | State / District | Title |
---|---|---|---|---|
March 29, 2022 | Kurt Schrader | D | OR-5 | Schrader Issues Statement Following FDA's Budget Request Includes His Proposal To Close Loophole in Generic Drug Approval Process |